-
Something wrong with this record ?
Local retrospective analysis of galactomannan cut-off values in bronchoalveolar lavage fluids for diagnosis of invasive aspergillosis
AP. Bellanger, H. Gbaguidi-Haore, N. Tatoyan, A. Berceanu, E. Scherer, L. Millon,
Language English Country United States
Document type Journal Article
- MeSH
- Aspergillus MeSH
- Aspergillosis diagnosis metabolism microbiology MeSH
- Biomarkers MeSH
- Bronchoalveolar Lavage Fluid * MeSH
- Immunocompromised Host MeSH
- Humans MeSH
- Mannans metabolism MeSH
- Reproducibility of Results MeSH
- Retrospective Studies MeSH
- Sensitivity and Specificity MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
Galactomannan antigen (GM) testing has been used for decades to screen immunocompromised patients for invasive aspergillosis (IA). Recent publications suggested that using a higher cut-off value than 0.5 in bronchoalveolar lavage fluid (BALF) could be more discriminant for hematology patients. We retrospectively analyzed the values of GM in BALF over 7 years (from 2010 to 2016). Performance indicators of the GM in BALF, according to three different cut-off values (0.5, 0.8, 1.5), were calculated using Stata 14.1. IA classification for hematology patients was based on European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria, as defined in 2008. A number of 716 GM were performed on BALF from 2010 to 2016 (597 patients) and 66 were positive (> 0.5). Among these 597 patients, 27 IA were diagnosed, 13 with a positive GM in BALF, 9 with a negative GM in BALF, and 5 unclassified IA (ICU patients). The analysis of performance indicators, based on our local data, did not demonstrate any significant difference using a higher cut-off value of GM in BALF. This result may be explained by the local recruitment of patients and by pre-analytic variations during BALF realization.
Department of Parasitology Mycology Besançon University Hospital Besançon France
Infection Control Department Besançon University Hospital Besançon France
Intensive Care Hematology Unit Besançon University Hospital Besançon France
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19002816
- 003
- CZ-PrNML
- 005
- 20190116123306.0
- 007
- ta
- 008
- 190116s2018 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12223-018-0618-z $2 doi
- 035 __
- $a (PubMed)29846912
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Bellanger, Anne-Pauline $u Department of Parasitology-Mycology, Besançon University Hospital, Besançon, France. apbellanger@chu-besancon.fr. Chrono-Environnement CNRS 6249 Research Team, Franche-Comté University, Besançon, France. apbellanger@chu-besancon.fr.
- 245 10
- $a Local retrospective analysis of galactomannan cut-off values in bronchoalveolar lavage fluids for diagnosis of invasive aspergillosis / $c AP. Bellanger, H. Gbaguidi-Haore, N. Tatoyan, A. Berceanu, E. Scherer, L. Millon,
- 520 9_
- $a Galactomannan antigen (GM) testing has been used for decades to screen immunocompromised patients for invasive aspergillosis (IA). Recent publications suggested that using a higher cut-off value than 0.5 in bronchoalveolar lavage fluid (BALF) could be more discriminant for hematology patients. We retrospectively analyzed the values of GM in BALF over 7 years (from 2010 to 2016). Performance indicators of the GM in BALF, according to three different cut-off values (0.5, 0.8, 1.5), were calculated using Stata 14.1. IA classification for hematology patients was based on European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria, as defined in 2008. A number of 716 GM were performed on BALF from 2010 to 2016 (597 patients) and 66 were positive (> 0.5). Among these 597 patients, 27 IA were diagnosed, 13 with a positive GM in BALF, 9 with a negative GM in BALF, and 5 unclassified IA (ICU patients). The analysis of performance indicators, based on our local data, did not demonstrate any significant difference using a higher cut-off value of GM in BALF. This result may be explained by the local recruitment of patients and by pre-analytic variations during BALF realization.
- 650 _2
- $a aspergilóza $x diagnóza $x metabolismus $x mikrobiologie $7 D001228
- 650 _2
- $a Aspergillus $7 D001230
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a bronchoalveolární lavážní tekutina $7 D001992
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunokompromitovaný pacient $7 D016867
- 650 _2
- $a mannany $x metabolismus $7 D008351
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a senzitivita a specificita $7 D012680
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gbaguidi-Haore, Houssein $u Infection Control Department, Besançon University Hospital, Besançon, France.
- 700 1_
- $a Tatoyan, Natacha $u Department of Parasitology-Mycology, Besançon University Hospital, Besançon, France.
- 700 1_
- $a Berceanu, Ana $u Intensive Care Hematology Unit, Besançon University Hospital, Besançon, France.
- 700 1_
- $a Scherer, Emeline $u Department of Parasitology-Mycology, Besançon University Hospital, Besançon, France. Chrono-Environnement CNRS 6249 Research Team, Franche-Comté University, Besançon, France.
- 700 1_
- $a Millon, Laurence $u Department of Parasitology-Mycology, Besançon University Hospital, Besançon, France. Chrono-Environnement CNRS 6249 Research Team, Franche-Comté University, Besançon, France.
- 773 0_
- $w MED00011005 $t Folia microbiologica $x 1874-9356 $g Roč. 63, č. 6 (2018), s. 757-761
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29846912 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190116 $b ABA008
- 991 __
- $a 20190116123518 $b ABA008
- 999 __
- $a ok $b bmc $g 1367993 $s 1040974
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 63 $c 6 $d 757-761 $e 20180530 $i 1874-9356 $m Folia microbiologica $n Folia microbiol. (Prague) $x MED00011005
- LZP __
- $a Pubmed-20190116
